Middle East And Africa Blood Plasma And Plasma Derived Medicinal Products Market
Market Size in USD Billion
CAGR :
% 
USD
1.34 Billion
USD
2.17 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 1.34 Billion |
 Market Size (Forecast Year) |
USD 2.17 Billion |
 CAGR |
% |
| Major Markets Players |
|
Middle East and Africa Blood Plasma & Plasma Derived Medicinal Products Market Segmentation, By Product (Immunoglobulins, Coagulation Factors (For Bleeding Disorders), Albumin (Plasma Volume Expander), Protease Inhibitors (For Genetic Deficiencies), Monoclonal Antibodies (Derived From Plasma Cells), and Other Plasma Derived Proteins), Application (Immunology, Hematology, Critical Care, Neurology, Pulmonology, Haemato-Oncology, Rheumatology, and Other Applications), Processing Technology (Ion Exchange Chromatography, Affinity Chromatography, Cryoprecipitation, Ultrafiltration, and Microfiltration), Mode (Modern and Traditional Plasma Fractionation), End-User (Hospitals & Clinics, Research Labs, Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others) - Industry Trends and Forecast to 2032
Blood Plasma and Plasma Derived Medicinal Products Market Size
- The Middle East and Africa blood plasma & plasma derived medicinal products market was valued at USD 1.340 billion in 2024 and is expected to reach USD 2.168 billion by 2032 at a CAGR of 6.25%, during the forecast period
- The market growth is largely fueled by the rising prevalence of rare and chronic diseases
- Furthermore, blood plasma & plasma derived medicinal products technological advancements in plasma fractionation. These converging factors are accelerating the uptake of blood plasma & plasma derived medicinal products solutions, thereby significantly boosting the industry's growth
Blood Plasma & Plasma Derived Medicinal Products Market Analysis
- The market is expanding due to increased demand for plasma-derived therapies in treating conditions like hemophilia, immunodeficiency disorders, and autoimmune diseases, supported by rising awareness and advancements in transfusion medicine
- Technological advancements in blood collection, fractionation, and cold chain logistics are enhancing product quality and shelf life, encouraging wider adoption across hospitals, trauma centers, and diagnostic laboratories globally
- South Africa is expected to dominate the blood plasma & plasma derived medicinal products market with 29.62% share due to improved healthcare infrastructure, rising demand for plasma therapies, increased government support, and growing prevalence of chronic and infectious diseases
- South Africa is expected to be the fastest growing region in the blood plasma & plasma derived medicinal products market due to increasing healthcare investments, rising prevalence of chronic and infectious diseases, improved diagnostic facilities, growing awareness about blood safety, and government initiatives to boost plasma therapy accessibility and infrastructure
- The immunoglobulins segment is expected to dominate the blood plasma & plasma derived medicinal products market with a 42.41% share in 2025 due to rising demand for targeted therapies, improved purification technologies, and increasing prevalence of immune-related disorders
Report Scope and Blood Plasma & Plasma Derived Medicinal Products Market Segmentation
|
Attributes |
Blood Plasma & Plasma Derived Medicinal Products Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
Middle East and Africa
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. |
Blood Plasma & Plasma Derived Medicinal Products Market Trends
“Rising Prevalence of Rare and Chronic Diseases”
- A major driving force behind the blood plasma & plasma derived medicinal products market is the increasing prevalence of rare and chronic diseases globally, fueled by advancements in diagnostic technologies and heightened awareness among healthcare providers and patients
- For instance, in April 2025, CDC data revealed that 76.4% of U.S. adults had at least one chronic condition, and 51.4% had multiple conditions. This rising trend—also observed among younger adults—has intensified the demand for lifelong care, particularly for conditions like hemophilia, primary immunodeficiency diseases, and von Willebrand disease
- Plasma-derived therapies such as immunoglobulins, coagulation factors, and albumin are critical for managing these lifelong conditions. Patients with Primary Immunodeficiency rely on IVIG for immune support, while hemophilia patients require regular clotting factor infusions to prevent bleeding episodes
- The global aging population further drives this trend, with older adults increasingly affected by conditions like liver cirrhosis, multiple myeloma, and inflammatory diseases, all of which necessitate plasma-derived interventions
- In March 2025, research published in PMC highlighted the immense global burden of rare diseases, especially among pediatric populations. Despite progress in genomic medicine and orphan drug development, delays in diagnosis and limited treatment options persist, underscoring the need for multidisciplinary and sustained care
- The growing demand for safe, effective, and high-quality plasma-derived therapies is a pivotal factor driving the blood plasma & plasma derived medicinal products market, as these products play a crucial role in managing lifelong diseases and addressing unmet Medicinal needs
Blood Plasma & Plasma Derived Medicinal Products Market Dynamics
Driver
“Expanding Geriatric Population”
- The increasing demand for blood plasma & plasma derived medicinal products is significantly driven by the aging global population, which is more prone to chronic and degenerative conditions such as immune system disorders, neurological diseases, liver complications, and blood-related issues that require plasma-based therapies including immunoglobulins, albumin, and clotting factors
- For instance, in March 2025, research featured in PMC analyzing US National Inpatient Sample (NIS) data from 2010 to 2024 revealed that the rapidly growing elderly population has led to a substantial rise in hospital admissions, longer hospital stays, and higher readmission rates. This trend, largely driven by chronic illnesses and multimorbidity, highlights the escalating strain on healthcare systems and the corresponding demand for plasma-derived treatments
- With advancing age, the immune system weakens, increasing susceptibility to infections and autoimmune disorders. Immunoglobulin therapies are frequently used in managing conditions such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), while albumin is vital in managing fluid balance during surgical procedures and critical care in elderly patients
- Countries which have high proportions of older adults, are witnessing a sustained rise in the consumption of PDMPs. This demographic trend places immense pressure on national healthcare systems to ensure uninterrupted supply chains and adequate plasma collection
- The projected increase in the global population aged 60 and above—from 1.1 billion in 2023 to 2.1 billion by 2050, as per WHO estimates—further emphasizes the crucial role of geriatric care. This demographic shift not only amplifies the need for long-term therapeutic support but also positions the elderly population as a key, enduring market segment for PDMPs
Restraint/Challenge
“High Cost and Complex Manufacturing Process”
- The high cost and complexity associated with the manufacturing of Blood Plasma & Plasma Derived Medicinal Products present a significant barrier to market expansion. The process requires stringent plasma collection protocols, extensive pathogen screening, and multi-step fractionation under sterile, GMP-compliant environments—making production highly resource-intensive and time-consuming
- For instance, a detailed analysis by Aykon Biosciences emphasized that manufacturing complex biologics such as plasma-derived therapies faces rising cost pressures due to expensive raw materials, skilled labor requirements, and increasingly strict regulatory compliance demands. The shift toward specialized and personalized therapies further elevates costs, necessitating advanced technologies and rigorous quality assurance systems
- Additionally, the manufacturing cycle for PDMPs can extend up to 12 months, requiring cold-chain logistics for storage and transportation throughout the process. These factors significantly increase capital and operational expenditures, limiting scalability and deterring smaller players and developing economies from participating effectively in the market
- The cost-intensive nature of production also contributes to high final product prices, which reduces accessibility and affordability—especially in low- and middle-income countries where healthcare budgets are constrained. This financial burden poses challenges in meeting growing global demand, thereby restraining broader adoption of PDMPs worldwide
- While ongoing technological innovation may gradually improve cost-efficiency, the current high production and processing costs remain a central restraint. Addressing these challenges through improved manufacturing technologies, expanded donor infrastructure, and supportive public health funding will be crucial for unlocking wider market access and equitable therapeutic coverage
Blood Plasma & Plasma Derived Medicinal Products Market Scope
The market is segmented on the basis of product, application, processing technology, mode, end user, and distribution channel.
- By Product
On the basis of product, the market is segmented into immunoglobulins, coagulation factors (for bleeding disorders), albumin (plasma volume expander), protease inhibitors (for genetic deficiencies), monoclonal antibodies (derived from plasma cells), and other plasma derived proteins. In 2025, the immunoglobulins segment is expected to dominate the market with a market share of 42.41% in 2025, driven by its rising immunodeficiency diagnoses, autoimmune diseases, and increasing intravenous immunoglobulin (IVIG) use.
The coagulation factors (for bleeding disorders) segment is anticipated to witness the fastest growth rate of 6.41% from 2025 to 2032, fueled by rising hemophilia cases, improved diagnostic access, government support, and expanding use of recombinant and plasma-derived therapies.
- By Application
On the basis of application, the market is segmented into immunology, hematology, critical care, neurology, pulmonology, haemato-oncology, rheumatology, and other applications. The immunology segment held the largest market revenue share in 2025, driven by its widespread use in treating primary immunodeficiencies, autoimmune disorders, and rising global demand for intravenous immunoglobulin (IVIG).
The immunology segment is expected to witness the fastest CAGR from 2025 to 2032, driven by increasing prevalence of autoimmune diseases, rising aging population, and expanding clinical applications of immunoglobulin therapies.
- By Processing Technology
On the basis of processing technology, the market is segmented into ion exchange chromatography, affinity chromatography, cryoprecipitation, ultrafiltration, and microfiltration. The ion exchange chromatography segment held the largest market revenue share in 2025, driven by high efficiency, scalability, and effectiveness in purifying plasma proteins like immunoglobulins, albumin, and coagulation factors.
The affinity chromatography segment is expected to witness the fastest CAGR from 2025 to 2032, favored for its high specificity, ability to isolate target proteins, and growing adoption in advanced biologics purification.
- By Mode
On the basis of mode, the market is segmented into modern and traditional plasma fractionation. The modern segment accounted for the largest market revenue share in 2025, driven advanced processing technologies, higher product purity, improved safety profiles, and increased adoption of recombinant and high-yield plasma-derived therapies.
The modern segment is expected to witness the fastest CAGR from 2025 to 2032, driven innovation in purification techniques, rising demand for safer biologics, and growing investments in next-generation plasma processing technologies.
- By End User
On the basis of end user, the market is segmented into hospitals & clinics, research labs, academic institutes, and others. The hospitals & clinics segment accounted for the largest market revenue share in 2025, driven by its high patient volume, availability of specialized care, increasing chronic disease treatments, and access to advanced plasma-derived therapies.
The hospitals & clinics segment is also expected to witness the fastest CAGR from 2025 to 2032, propelled by expanding healthcare infrastructure, rising inpatient admissions, and growing reliance on plasma therapies for complex conditions.
- By Distribution Channel
On the basis of distribution channel, the market is segmented into direct tender, third party distributors, and others. The direct tender segment accounted for the largest market revenue share in 2025, driven by the bulk purchasing by government bodies, cost-efficiency, assured supply chains, and increasing public sector investments in plasma-derived medicinal products.
The direct tender segment is also expected to witness the fastest CAGR from 2025 to 2032, propelled by expanding government healthcare programs, centralized procurement policies, and rising demand for cost-effective, large-scale plasma therapy distribution.
Blood Plasma & Plasma Derived Medicinal Products Market Regional Analysis
- South Africa dominates the blood plasma & plasma derived medicinal products market with the largest revenue share of 29.62% and is projected to grow at the fastest CAGR of 7.42% in 2025, driven by advanced healthcare infrastructure, increased diagnosis rates of rare and chronic diseases, and high per capita healthcare expenditure
- The country’s strong regulatory framework, robust reimbursement systems, and presence of major market players such as Grifols, CSL Behring, and Takeda contribute to Middle East and Africa leadership in plasma collection and therapy distribution
- Major economies are investing heavily in biopharmaceutical R&D, expanding plasma collection networks, and improving access to plasma-derived therapies for immunology, hematology, and neurology
Saudi Arabia Blood Plasma & Plasma Derived Medicinal Products Market Insight
The Saudi Arabia is projected to witness strong growth from 2025 to 2032 in the Middle East and Africa region in 2025, attributed to its well-established healthcare ecosystem, growing patient pool for rare and chronic conditions, and robust government initiatives promoting plasma donation. The country's large number of plasma collection centers and accelerated approvals for PDMPs enhance treatment accessibility and drive market expansion.
U.A.E. Blood Plasma & Plasma Derived Medicinal Products Market Insight
U.A.E. is expected to register a significant CAGR in the region from 2025 to 2032, driven by its universal healthcare system, rising awareness of rare disorders, and government investments in expanding domestic plasma collection capabilities. Strategic partnerships and advancements in biologics manufacturing are strengthening in the PDMPs landscape.
Blood Plasma & Plasma Derived Medicinal Products Market Share
The blood plasma & plasma derived medicinal products industry is primarily led by well-established companies, including:
- CSL (Australia)
- Takeda Pharmaceutical Company Limited (Japan)
- Grifols, S.A. (Spain)
- Octapharma AG (Switzerland)
- Kedrion (Italy)
- Biotest AG (Germany)
- Fresenius Kabi AG (Germany)
- Kamada Pharmaceuticals (Israel)
- KM Biologics (Japan)
- Reliance Life Sciences (India)
- SK Plasma (South Korea)
- Synthaverse S. A. (Poland)
- VIRCHOW BIOTECH (India)
Latest Developments in Blood Plasma & Plasma Derived Medicinal Products Market
- In November 2024, CSL Plasma expanded its adoption of the advanced Rika Plasma Donation System across six U.S. donation centers near Denver, Colorado. These new devices, developed jointly with Terumo Blood & Cell Technologies, cut collection times by ~30% while improving donor comfort, safety, and efficiency
- In December 2022, CSL inaugurated its new Broadmeadows Plasma Fractionation Facility in Victoria, Australia—the largest plasma grain-processing site in the Southern Hemisphere. With capacity to handle 9.2 million plasma-equivalent liters annually, this USD 900 million facility supports the global demand for plasma-based therapies that treat immunodeficiencies, neurological disorders, and critical conditions like transplants and burns
- In June 2024, Takeda announced a USD 30 million expansion of its Los Angeles plasma‑fractionation facility, its global leader per capacity. This upgrade is expected to add up to 2 million liters/year of production volume, helping to meet rising global demand for plasma‑derived therapies used in treating immunodeficiencies and bleeding disorders
- In 2023, Takeda committed approximately USD 765 million to build a new plasma‑derived therapy manufacturing plant in Osaka, Japan—nearly quintupling capacity at its existing Narita site. This facility is projected to be fully operational by 2030 and will serve both the Japanese and global markets
- In March 2025, Grifols partnered with Inpeco to integrate advanced automation robotics (FlexLab X), diagnostics, and reagents, creating “labs of the future” for high‑throughput, safer, traceable blood and plasma testing in transfusion Medicine labs analyze biological samples to diagnose, monitor, and research diseases
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.1.1 POLITICAL FACTORS
4.1.2 ECONOMIC FACTORS
4.1.3 SOCIAL FACTORS
4.1.4 TECHNOLOGICAL FACTORS
4.1.5 ENVIRONMENTAL FACTORS
4.1.6 LEGAL FACTORS
4.2 PORTER’S FIVE FORCES
4.2.1 THREAT OF NEW ENTRANTS
4.2.2 BARGAINING POWER OF SUPPLIERS
4.2.3 BARGAINING POWER OF BUYERS
4.2.4 THREAT OF SUBSTITUTES
4.2.5 INDUSTRY RIVALRY
4.3 SUPPLY CHAIN IMPACT ON THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET
4.3.1 OVERVIEW
4.3.2 RAW MATERIAL AVAILABILITY
4.3.3 MANUFACTURING CAPACITY
4.3.4 LOGISTICS AND LAST-MILE HURDLES
4.3.5 PRICING MODELS AND MARKET POSITIONING
4.4 INNOVATION STRATEGIES
4.4.1 KEY INNOVATION STRATEGIES
4.4.2 EMERGING DELIVERY TECHNIQUES
4.4.3 STRATEGIC IMPLICATIONS
4.4.4 CONCLUSION
4.5 RISK AND MITIGATION
4.6 VENDOR SELECTION DYNAMICS
4.6.1 PRODUCT QUALITY AND REGULATORY COMPLIANCE
4.6.2 SUPPLY CHAIN CAPABILITIES AND RELIABILITY
4.6.3 CLINICAL EFFICACY AND INNOVATION
4.6.4 COST COMPETITIVENESS AND REIMBURSEMENT COMPATIBILITY
4.6.5 LOCAL MARKET PRESENCE AND SUPPORT INFRASTRUCTURE
4.6.6 ETHICAL SOURCING, ESG COMPLIANCE, AND TRANSPARENCY
4.6.7 CONCLUSION
4.7 TARIFFS AND THEIR IMPACT ON MARKET
4.7.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS
4.7.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE
4.7.3 VENDOR SELECTION CRITERIA DYNAMICS
4.7.4 IMPACT ON SUPPLY CHAIN
4.7.5 IMPACT ON PRICES
4.7.6 REGULATORY INCLINATION
4.7.6.1 GCC TRADE ALIGNMENT & FTAS
4.7.6.2 SPECIAL ZONES AND RE-EXPORT MODELS
4.7.6.3 LOCAL SUBSIDY & POLICY RESPONSE
4.7.6.4 DOMESTIC COURSE OF CORRECTION
5 REGULATION COVERAGE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF RARE AND CHRONIC DISEASES
6.1.2 EXPANDING GERIATRIC POPULATION
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN PLASMA FRACTIONATION
6.1.4 GOVERNMENT AND INSTITUTIONAL SUPPORT
6.2 RESTRAINTS
6.2.1 HIGH COST AND COMPLEX MANUFACTURING PROCESS
6.2.2 LACK OF PLASMA SUPPLY AND DONOR
6.3 OPPORTUNITIES
6.3.1 ADVANCEMENTS IN PLASMA PROCESSING TECHNOLOGIES TO ENHANCE YIELD AND REDUCE COSTS
6.3.2 REIMBURSEMENT FRAMEWORKS AND INCREASED GOVERNMENTAL FOCUS ON RARE DISEASE TREATMENT
6.3.3 STRATEGIC ALLIANCES, MERGERS, AND ACQUISITIONS TO STRENGTHEN MIDDLE EAST AND AFRICA MARKET PENETRATION
6.4 CHALLENGES
6.4.1 COMPETITIVE PRESSURE FROM RECOMBINANT AND ALTERNATIVE BIOLOGICAL THERAPIES
6.4.2 INFRASTRUCTURE LIMITATIONS IN COLD CHAIN LOGISTICS IMPACTING PRODUCT DISTRIBUTION
7 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 IMMUNOGLOBULINS
7.3 COAGULATION FACTORS (FOR BLEEDING DISORDERS)
7.4 ALBUMIN (PLASMA VOLUME EXPANDER)
7.5 PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)
7.6 MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS)
7.7 OTHER PLASMA DERIVED PROTEINS
8 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 IMMUNOLOGY
8.3 HEMATOLOGY
8.4 CRITICAL CARE
8.5 NEUROLOGY
8.6 PULMONOLOGY
8.7 HAEMATO-ONCOLOGY
8.8 RHEUMATOLOGY
8.9 OTHER APPLICATIONS
9 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 ION EXCHANGE CHROMATOGRAPHY
9.3 AFFINITY CHROMATOGRAPHY
9.4 CRYOPRECIPITATION
9.5 ULTRAFILTRATION
9.6 MICROFILTRATION
10 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE
10.1 OVERVIEW
10.2 MODERN
10.3 TRADITIONAL PLASMA FRACTIONATION
11 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS & CLINICS
11.3 RESEARCH LABS
11.4 ACADEMIC INSTITUTES
11.5 OTHERS
12 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 THIRD PARTY DISTRIBUTORS
12.4 OTHERS
13 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 U.A.E.
13.1.4 ISRAEL
13.1.5 EGYPT
13.1.6 BAHRAIN
13.1.7 KUWAIT
13.1.8 OMAN
13.1.9 QATAR
13.1.10 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 CSL
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 GRIFOLS, S.A.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 OCTAPHARMA AG
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 KEDRION
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 ADMA BIOLOGICS, INC
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 AEGROS
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BHARAT SERUMS
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 BIOTEST AG.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 FRESENIUS KABI AG
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 GC BIOPHARMA CORPORATE
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 ICHOR
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 INTAS PHARMACEUTICALS LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 KAMADA PHARMACEUTICALS
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 KM BIOLOGICS
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 LFB
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 PLASMAGEN BIOSCIENCES PVT. LTD.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 PROLIANT HEALTH & BIOLOGICALS
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 PROMEA
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 RELIANCE LIFE SCIENCES
16.20.1 COMPANY SNAPSHOT
16.20.2 BUSINESS PORTFOLIO
16.20.3 RECENT DEVELOPMENT
16.21 SICHUAN YUANDA SHYUANG PHARMACEUTICAL CO., LTD.
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
16.22 SK PLASMA
16.22.1 COMPANY SNAPSHOT
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENT
16.23 SYNTHAVERSE S. A.
16.23.1 COMPANY SNAPSHOT
16.23.2 REVENUE ANALYSIS
16.23.3 PRODUCT PORTFOLIO
16.23.4 RECENT DEVELOPMENTS
16.24 TAIBANG BIO GROUP CO., LTD
16.24.1 COMPANY SNAPSHOT
16.24.2 PRODUCT PORTFOLIO
16.24.3 RECENT DEVELOPMENT
16.25 VIRCHOW BIOTECH
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 REGULATORY FRAMEWORK AND GUIDELINES
TABLE 2 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA COAGULATION FACTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA FACTOR IX IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA FACTOR VIII IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA FIBRINOGEN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA VON WILLEBRAND FACTOR (VWF) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 18 IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA ALBUMIN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS )IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2025-2032 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA IMMUNOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA HEMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA CRITICAL CARE IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA NEUROLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA PULMONOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA HEMATOLOGY -ONCOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA RHEUMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA OTHER APPLICATIONS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY, 2025-2032 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA ION EXCHANGE CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA AFFINITY CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA CRYOPRECIPITATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA ULTRAFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA MICROFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2025-2032 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA MODERN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA TRADITIONAL PLASMA FRACTIONATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2025-2032 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA HOSPITALS & CLINICS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA RESEARCH LABS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA ACADEMIC INSTITUTES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA OTHERS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA DIRECT TENDERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA THIRD PARTY DISTRIBUTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA OTHERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MIDDLE EAST AND AFRICA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 79 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 80 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 81 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 82 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 83 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 84 SOUTH AFRICA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 SOUTH AFRICA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 SOUTH AFRICA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 SOUTH AFRICA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 SOUTH AFRICA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 SOUTH AFRICA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 SOUTH AFRICA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 SOUTH AFRICA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 SOUTH AFRICA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 SOUTH AFRICA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 SOUTH AFRICA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 SOUTH AFRICA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 SOUTH AFRICA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 SOUTH AFRICA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 SOUTH AFRICA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 SOUTH AFRICA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 SOUTH AFRICA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 SOUTH AFRICA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 SOUTH AFRICA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 105 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 106 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 107 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 108 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 109 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 110 SAUDI ARABIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 SAUDI ARABIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 SAUDI ARABIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 SAUDI ARABIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 SAUDI ARABIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 SAUDI ARABIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 SAUDI ARABIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 SAUDI ARABIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 SAUDI ARABIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 SAUDI ARABIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 SAUDI ARABIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 SAUDIA ARABIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 SAUDI ARABIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 SAUDI ARABIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 SAUDI ARABIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 SAUDI ARABIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 SAUDI ARABIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 SAUDI ARABIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 SAUDI ARABIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 131 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 132 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 133 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 134 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 135 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 136 U.A.E. IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 U.A.E. INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 U.A.E. INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 U.A.E. COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 U.A.E. FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 U.A.E. RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 U.A.E. FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 U.A.E. RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 U.A.E. FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 U.A.E. PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 U.A.E. VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 U.A.E. FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 U.A.E. FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 U.A.E ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 U.A.E. PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 U.A.E. ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 U.A.E. C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 U.A.E MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 U.A.E. OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 U.A.E. ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 157 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 158 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 159 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 160 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 161 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 162 ISRAEL IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 ISRAEL INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 ISRAEL INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 ISRAEL COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 ISRAEL FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 ISRAEL RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 ISRAEL FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 ISRAEL RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 ISRAEL FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 ISRAEL PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 ISRAEL VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 ISRAEL FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 ISRAEL FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 ISRAEL ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 ISRAEL PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 ISRAEL ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 ISRAEL C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 ISRAEL MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 ISRAEL OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 ISRAEL ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 183 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 184 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 185 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 186 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 187 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 188 EGYPT IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 EGYPT INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 EGYPT INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 EGYPT COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 EGYPT FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 EGYPT RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 EGYPT FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 EGYPT RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 EGYPT FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 EGYPT PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 EGYPT VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 EGYPT FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 EGYPT FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 EGYPT ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 EGYPT PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 EGYPT ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 EGYPT C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 EGYPT MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 EGYPT OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 EGYPT ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 209 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 210 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 211 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 212 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 213 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 214 BAHRAIN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 BAHRAIN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 BAHRAIN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 BAHRAIN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 BAHRAIN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 BAHRAIN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 BAHRAIN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 BAHRAIN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 BAHRAIN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 BAHRAIN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 224 BAHRAIN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 BAHRAIN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 BAHRAIN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 BAHRAIN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 BAHRAIN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 BAHRAIN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 BAHRAIN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 BAHRAIN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 BAHRAIN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 BAHRAIN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 235 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 236 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 237 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 238 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 239 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 240 KUWAIT IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 241 KUWAIT INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 KUWAIT INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 KUWAIT COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 244 KUWAIT FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 KUWAIT RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 KUWAIT FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 KUWAIT RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 248 KUWAIT FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 249 KUWAIT PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 KUWAIT VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 KUWAIT FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 KUWAIT FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 KUWAIT ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 KUWAIT PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 KUWAIT ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 KUWAIT C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 KUWAIT MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 KUWAIT OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 KUWAIT ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 261 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 262 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 263 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 264 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 265 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 266 OMAN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 OMAN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 OMAN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 OMAN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 OMAN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 OMAN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 OMAN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 OMAN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 OMAN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 OMAN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 OMAN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 OMAN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 278 OMAN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 OMAN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 OMAN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 OMAN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 OMAN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 OMAN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 OMAN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 OMAN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 287 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 288 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 289 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 290 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 291 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 292 QATAR IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 QATAR INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 QATAR INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 QATAR COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 QATAR FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 297 QATAR RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 QATAR FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 QATAR RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 QATAR FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 QATAR PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 QATAR VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 303 QATAR FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 QATAR FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 QATAR ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 QATAR PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 QATAR ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 308 QATAR C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 QATAR MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 QATAR OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 QATAR ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 313 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 314 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 315 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 316 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 317 REST OF MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION
FIGURE 12 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT (2024)
FIGURE 13 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 RISING PREVALENCE OF RARE AND CHRONIC DISEASES IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 16 IMMUNOGLOBULINS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 17 PORTER’S FIVE FORCES
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES FOR THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET
FIGURE 19 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2024
FIGURE 20 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2025-2032 (USD THOUSAND)
FIGURE 21 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, CAGR (2025-2032) (2025-2032)
FIGURE 22 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2024
FIGURE 24 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)
FIGURE 25 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, CAGR (2025-2032) (2025-2032)
FIGURE 26 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2024
FIGURE 28 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2025-2032 (USD THOUSAND)
FIGURE 29 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, CAGR (2025-2032) (2025-2032)
FIGURE 30 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2024
FIGURE 32 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2025-2032 (USD THOUSAND)
FIGURE 33 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, CAGR (2025-2032) (2025-2032)
FIGURE 34 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2024
FIGURE 36 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 37 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, CAGR (2025-2032) (2025-2032)
FIGURE 38 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 40 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 41 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032) (2025-2032)
FIGURE 42 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SNAPSHOT (2024)
FIGURE 44 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY SHARE 2024 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
